P036 | A-AVD VERSUS ABVD IN FIRST-LINE STAGE IV CLASSICAL HODGKIN LYMPHOMA: EFFICACY AND TOXICITY IN A SINGLE CENTER EXPERIENCE

Brentuximab Vedotin combined with AVD (A-AVD) is the new standard for first-line advanced-stage Hodgkin Lymphoma (HL). The ECHELON-1 trial showed improved 7-year PFS (82.3% vs 74.5%) and OS (93.5% vs 88.8%) with A-AVD compared to ABVD. Nevertheless, the enhanced survival outcomes may be accompanied...

Descripció completa

Dades bibliogràfiques

Autors principals:	M. Cristante, F. Fallanca, C. Martinenghi, M.C. Quattrocchi, T. Calimeri, P. Angelillo, E. Flospergher, F. Erbella, G. Cassanello, A.J.M. Ferreri, F. Marino
Format:	Artigo
Idioma:	Inglês
Publicat:	Ferrata Storti Foundation 2025-09-01
Col·lecció:	Haematologica
Accés en línia:	https://haematologica.org/article/view/12533
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!